Curza
Salt Lake City
About Curza
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $24.2M
- Last round: Series Unknown (Jul 2019)
- Website: curza.com
- Phone: (617) 575-2202
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/curza-79835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.